PurposeBio is a UCLA tech spinout, with strong roots in The Weizmann Institute in Israel.
Synthetic Biology Breakthrough Platform - engineered enzymes with specific targeted modification capabilities on secondary Bile Acids.
NAFLD and Hyperlipidemia first indication. Bile Acid related disease in pipeline.
Co-Founder Dr. Elaine Hsiao (UCLA) and Scientific Chair, Prof. Eran Elinav from The Weizmann Institute, are both world leaders in our field.
- $80Billion market targets
- In-Vivo Proof Of Concept
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
LBP
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
